Essaji Yasmin, Rocha Flavio G
Section of General, Thoracic and Vascular Surgery, Virginia Mason Medical Center, Seattle, Washington, USA.
Division of Surgical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
J Surg Oncol. 2021 May;123(6):1467-1474. doi: 10.1002/jso.26382.
Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long-term survival. In the mid-1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5-fluorouracil-based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.
在过去30年中，胰腺癌的辅助治疗经历了范式转变。20世纪90年代以前，手术是主要治疗方法，发病率高且长期生存率极低。20世纪80年代中期，胃肠道肿瘤研究组（GITSG）显示，基于5-氟尿嘧啶的放化疗可使总生存期从11个月翻倍至20个月，而现在的PRODIGE试验显示了FOLFIRINOX方案的益处，目前最长总生存期接近5年。关于治疗药物、疗程和顺序的进一步研究仍在进行中。
